SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Allogene Therapeutics logo
2 months ago

Director, Global Medical Information & Scientific Communications

Allogene Therapeutics

South San Francisco, CA (Remote)Full time$200K/yr – $250K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Allogene Therapeutics logo

Director, Global Medical Information & Scientific Communications

Allogene Therapeutics

South San Francisco, CA (Remote)

$200K/yr - $250K/yrIn-houseFull-timeDirector/executive4+ years exp.
2 months ago
Allogene Therapeutics logo
Allogene Therapeutics

Director, Global Medical Information & Scientific Communications

South San Francisco, CA (Remote)

$200K/yr – $250K/yrDirector/Executive4+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the Medical Information, Medical Communications, and Publications lifecycle for ALPHA3 assets, turning complex data into clear, regulatory-compliant outputs for external stakeholders while coordinating cross-functional teams and external partners.

  • Lead MI responses, SOPs, and library maintenance across pipeline assets.
  • Drive MC deliverables and scientific materials through reviews and warehousing with internal/external partners.
  • Oversee publications planning and external-author collaboration in line with GPP/ICMJE standards.

Job Description

Responsibilities

  • Lead Medical Information (MI) support for assigned pipeline assets, including development of processes and SOPs for intake/triage of unsolicited inquiries, development of scientifically balanced responses, and documentation of inquiry handling. Maintain the Medical Information (MI) content library (e.g., SRLs, FAQs, and non-standard response letters) across pipeline assets.
  • Drive Medical Communications (MC) for assigned pipeline assets in partnership with internal stakeholders and external vendors/agencies, including development of the scientific platform and creation/review of scientific communication deliverables (e.g., slide decks, congress materials, FAQs, field medical materials) through MRC review and warehousing.
  • Lead publications planning and execution for assigned pipeline assets in alignment with Good Publication Practice (GPP) and authorship standards (e.g., ICMJE), including publication plan development, review committee coordination, and support of abstracts, posters/orals, and manuscripts with external authors.
  • Engage and maintain relationships with external scientific stakeholders (e.g., investigators, KOLs, and societies) to support publication and trial site support activities as needed.
  • Ensure all activities adhere to applicable regulations and company policies, including appropriate use of approved materials, documentation standards, and medical/legal/regulatory review requirements.
  • Maintain scientific expertise in relevant disease areas with the ability to translate complex data into clear, audience-appropriate scientific content.
  • Execute Field Medical-aligned activities for assigned ALPHA3 global study sites in, (e.g., site education and/or scientific discussions as requested).
  • Other duties as assigned.

Requirements

  • Advanced degree in life sciences field (APN, PhD, PharmD, MD)
  • 4-6+ years of experience in Medical Affairs (Medical Information, Medical Communications, Publications, or a combination), within the pharmaceutical/biotech industry; experience supporting pipeline/launch readiness preferred.
  • Working understanding of medical affairs principles, the end-to-end lifecycle of scientific content (e.g., MI response documents, medical communications materials, and publications), building HCP relationships, and engaging in scientific exchange.
  • Willingness to travel (up to ~40% of time, including overnight travel) to support global ALPHA3 sites and attend internal meetings and scientific congresses, as needed.
  • Excellent communication, presentation, and time management skills required; must be adaptable and able to work well within a team and relate effectively with people at all levels of the organization
  • Familiarity with applicable legal, regulatory, and compliance requirements for scientific exchange and clinical trial site interactions; ability to operate compliantly across multiple geographies.
  • Ability to partner with key internal stakeholders to understand key objectives and to drive plans that achieve or exceed these
  • Ability to effectively work in a fast-paced, biotech environment, while dealing with ambiguity and ability to work independently and as part of a team
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines and strong interpersonal skills including verbal and written communication are essential in this collaborative work environment
  • Candidates must be authorized to work in the U.S. and able to travel internationally for business (i.e., obtain/maintain a valid passport and any required visas/entry documentation, as needed).

Preferred

  • Experience supporting pipeline/launch readiness is preferred.

Benefits

  • annual performance bonus
  • equity
  • health insurance
  • generous time off (including 2 annual holiday company-wide shutdowns)
Allogene Therapeutics logo

Allogene Therapeutics

4.0 Glassdoor

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelinesPlease be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

Founded in 2017
South San Francisco, California, USA
203 employees (4 in marketing)
www.allogene.com
78% recommend to a friend
82% CEO approval

Traffic Signals

Monthly Visitors
19.5K
Monthly Google Ads Budget
$29.1K
Traffic Source Mix
Search
38.2%
Direct
42.7%
Referral
10.5%
Social
7%
Paid
1.5%

Headcount Trend

Current headcount: ~203

Marketing Team

Marketing Team Size
4 (2% of company)

Funding

Total Funding
$891.8M
Last Raise
Post IPO Equity, 2 years ago

Recent News

Detecting support and resistance levels for Allogene Therapeutics Inc. - Market Movement Recap & Step-by-Step Trade Execution Guides
Nov 20, 2025 • newser.com
Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy
Nov 18, 2025 • Investing.com Nigeria
Risk adjusted return profile for Allogene Therapeutics Inc. analyzed - Quarterly Earnings Summary & Low Risk Entry Point Guides
Nov 15, 2025 • newser.com
Allogene Therapeutics (ALLO) Receives a Buy from H.C. Wainwright
Nov 12, 2025 • The Globe and Mail
Positive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial Position
Nov 10, 2025 • TipRanks
Allogene (NASDAQ: ALLO) to join 3 conferences: TD Cowen, Jefferies London, Piper Sandler
Nov 10, 2025 • Stock Titan
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Nov 10, 2025 • GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Halozyme (HALO) and Progyny (PGNY)
Nov 8, 2025 • The Globe and Mail
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2025 Earnings Call Transcript
Nov 8, 2025 • Insider Monkey
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
Nov 7, 2025 • Yahoo Finance
Allogene Therapeutics (ALLO) Gets a Buy from Oppenheimer
Nov 7, 2025 • The Globe and Mail
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T (ALLO)
Nov 7, 2025 • Seeking Alpha
Allogene Therapeutics: Q3 Earnings Snapshot
Nov 6, 2025 • New Haven Register
Allogene Therapeutics (NASDAQ: ALLO) posts $41.4M loss, ends with $277.1M cash
Nov 6, 2025 • Stock Titan
Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
Nov 6, 2025 • Yahoo Finance
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
Nov 3, 2025 • GlobeNewswire
Allogene to present pivotal trial design for lymphoma therapy at ASH
Nov 3, 2025 • Investing.com
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
Nov 3, 2025 • Sahm
Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT
Oct 30, 2025 • Stock Titan
Allogene CFO Parker sells $46k in shares
Oct 23, 2025 • Investing.com
Is Allogene Therapeutics Inc. stock poised for growth - 2025 Technical Overview & High Accuracy Trade Alerts
Oct 20, 2025 • newser.com
Will Allogene Therapeutics Inc. stock beat EPS estimates - July 2025 Weekly Recap & Daily Stock Trend Reports
Oct 17, 2025 • nchmf.gov.vn
Allogene Therapeutics Faces Potential Patent Infringement Issues
Oct 14, 2025 • TradingView
JP Morgan Downgrades Allogene Therapeutics (ALLO) to Underweight
Oct 10, 2025 • GuruFocus
Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
Oct 10, 2025 • TipRanks
Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook
Oct 10, 2025 • Seeking Alpha
Allogene stock downgraded by JPMorgan on concerns over program changes
Oct 10, 2025 • Investing.com
Allogene Therapeutics at Citi’s SMID Call Series: Strategic Insights
Oct 3, 2025 • Investing.com
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
Sep 12, 2025 • Yahoo Finance
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
Sep 12, 2025 • Nasdaq
Capsida Reports Patient Death in Gene Therapy Trial
Sep 11, 2025 • BioSpace
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline
Sep 2, 2025 • Investing.com
Leading AlloCAR T Developer Allogene Therapeutics to Share Updates at Citi Biopharma Summit
Aug 27, 2025 • Stock Titan
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Aug 27, 2025 • MarketScreener
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript
Aug 15, 2025 • Insider Monkey
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Aug 14, 2025 • Zacks Investment Research
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Aug 14, 2025 • Yahoo Finance
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Aug 14, 2025 • Nasdaq
Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
Aug 14, 2025 • Seeking Alpha
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025
Aug 14, 2025 • MarketScreener
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position
Aug 13, 2025 • Stock Titan
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
Aug 13, 2025 • Investing.com
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Aug 13, 2025 • Yahoo Finance
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Aug 13, 2025 • Allogene Therapeutics, Inc.
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect
Aug 12, 2025 • Yahoo Finance
A Look at Allogene Therapeutics's Upcoming Earnings Report
Aug 12, 2025 • Benzinga.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13
Aug 6, 2025 • Quiver Quantitative
Allogene Therapeutics Upcoming Q2 Earnings: Latest Updates on CAR T-Cell Cancer Therapy Progress
Aug 6, 2025 • Stock Titan
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Aug 6, 2025 • Allogene Therapeutics, Inc.
Fatal Adverse Event Leads Allogene to Discontinue Novel Monoclonal Antibody, Adjust Cema-Cel Trial Protocol for Large B-Cell Lymphoma
Aug 4, 2025 • Pharmaceutical Executive
Allogene ditches enhanced lymphodepletion | ApexOnco - Clinical Trials news and analysis
Aug 4, 2025 • Oncology Pipeline
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
Aug 4, 2025 • Investing.com
Patient death in Allogene trial
Aug 4, 2025 • Pharma Letter
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial
Aug 4, 2025 • BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Aug 4, 2025 • Benzinga.com
Regeneron cancer bispecific rejected again; Allogene discloses trial death
Aug 1, 2025 • BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event
Aug 1, 2025 • Investing.com
Allogene's cell therapy conditioning mAb linked to patient death
Aug 1, 2025 • FirstWord Pharma
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design
Aug 1, 2025 • Endpoints News
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
Aug 1, 2025 • TipRanks
Allogene Therapeutics Pivots ALPHA3 Trial Strategy: Adopts Standard FC Protocol After Safety Review
Aug 1, 2025 • Stock Titan
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Aug 1, 2025 • Yahoo Finance
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges
Aug 1, 2025 • StocksToTrade
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Aug 1, 2025 • GlobeNewswire
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board | ALLO Stock News
Aug 1, 2025 • Quiver Quantitative
Allogene Therapeutics price target lowered by $2 at Oppenheimer, here's why
Aug 1, 2025 • thefly.com
Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
Aug 1, 2025 • thefly.com
Allogene reports patient death, discontinues investigational antibody in CAR-T pivotal trial
Aug 1, 2025 • FierceBiotech
Allogene Resets Clinical Course After Patient Death In Lymphoma Study
Aug 1, 2025 • Benzinga.com
To speed patient access, Allogene scales up CAR T cell products
Jul 30, 2025 • Drug Discovery News
Global Allogeneic Cell Therapy Market to grow at 25% CAGR on rising demand and trials by 2030
Jul 25, 2025 • PharmiWeb
Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors
Jul 24, 2025 • 富途牛牛
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Jul 23, 2025 • PR Newswire
Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T
Jun 12, 2025 • GuruFocus
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
Jun 12, 2025 • Yahoo Finance
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Jun 12, 2025 • simplywall.st
Allogene Therapeutics' ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma
Jun 4, 2025 • CRISPR Medicine News
Allogene Therapeutics at Jefferies Conference: Delays and Optimism
Jun 4, 2025 • Investing.com
ASCO25: CAR-Ts from Allogene, Gilead show early promise in solid tumours
Jun 2, 2025 • FirstWord Pharma
Citi maintains buy rating on Allogene stock following ASCO data
Jun 2, 2025 • Investing.com
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Jun 1, 2025 • Allogene
Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025
Jun 1, 2025 • Nasdaq
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
May 29, 2025 • Seeking Alpha
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events
May 23, 2025 • Stock Titan
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 23, 2025 • Allogene
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 23, 2025 • Allogene Therapeutics, Inc.
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
May 22, 2025 • Yahoo Finance
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
May 22, 2025 • Allogene
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
May 15, 2025 • Yahoo Finance
Layoffs hit CAR-T developers Allogene, Kyverna
May 14, 2025 • FirstWord Pharma
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
May 14, 2025 • Yahoo Finance
Allogene Therapeutics (ALLO) Stock Drops Amid Trial Delays
May 14, 2025 • GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results
May 14, 2025 • Seeking Alpha
Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates
May 14, 2025 • Fierce Biotech
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum
May 14, 2025 • Seeking Alpha
Allogene Earnings Update: Clinical Trials Advance as Cash Runway Extends to 2027, ASCO Data Coming
May 13, 2025 • Stock Titan
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
May 13, 2025 • Yahoo Finance
Earnings call transcript: Allogene Therapeutics reports Q1 2025 loss
May 13, 2025 • Investing.com
Allogene Therapeutics GAAP EPS of -$0.28 in-line
May 13, 2025 • Seeking Alpha
Earnings Scheduled For May 13, 2025
May 13, 2025 • Benzinga.com